Personalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD TestingBusiness Wire • 10/16/25
CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal TestBusiness Wire • 09/10/25
Personalis Announces New Data from a Landmark Neoadjuvant Lung Cancer Trial Showing Superiority of Ultra-Sensitive, Tumor-Informed MRD TestingBusiness Wire • 09/03/25
Down 27.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Personalis (PSNL)Zacks Investment Research • 08/13/25
After Plunging 30.5% in 4 Weeks, Here's Why the Trend Might Reverse for Personalis (PSNL)Zacks Investment Research • 08/12/25
All You Need to Know About Personalis (PSNL) Rating Upgrade to BuyZacks Investment Research • 08/08/25
Super Micro Computer Posts Downbeat Q4 Results, Joins Personalis, Snap And Other Big Stocks Moving Lower In Wednesday's Pre-Market SessionBenzinga • 08/06/25
Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer PatientsBusiness Wire • 07/09/25
Personalis (PSNL) Surges 14.2%: Is This an Indication of Further Gains?Zacks Investment Research • 07/03/25
Personalis (PSNL) Soars 7.3%: Is Further Upside Left in the Stock?Zacks Investment Research • 06/17/25
Personalis' NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCOBusiness Wire • 06/03/25
New Data Shows NeXT Personal® Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for RelapseBusiness Wire • 06/02/25
Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Assay for Residual Cancer and Recurrence DetectionBusiness Wire • 05/22/25
Personalis to Participate at the Craig-Hallum 22nd Annual Investor ConferenceBusiness Wire • 05/14/25